Imunon Inc
IMNN1.140USD
+0.724+174.37%
Close 05/23, 16:00（ET）Quotes delayed by 15 min
16.67MMarket Cap
LossP/E TTM
More Details of Imunon Inc Company
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Company Info
Company codeIMNN
Company nameImunon Inc
IPO dateOct 27, 1993
Founded at2000
CEODr. Stacy R. Lindborg, Ph.D.
Number of employees25
Security typeOrdinary Share
Fiscal year-endOct 27
Address997 Lenox Dr Ste 100
CityLAWRENCEVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08648
Phone16098969100
Websitehttps://imunon.com/
Company codeIMNN
IPO dateOct 27, 1993
Founded at2000
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David (Dave) Gaiero, CPA
Mr. David (Dave) Gaiero, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Shareholder Statistics
Shareholder
Proportion
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
1.68%
Individual Investor
1.52%
Investment Advisor
0.41%
Venture Capital
0.15%
Hedge Fund
0.10%
Other
96.14%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
49
648.18K
4.43%
-1.83M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
2023Q1
80
515.97K
6.03%
-572.90K
2022Q4
81
529.26K
7.22%
-671.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Geode Capital Management, L.L.C.
139.50K
0.95%
+13.57K
+10.78%
Dec 31, 2024
Tardugno (Michael H)
69.14K
0.47%
+27.63K
+66.55%
Feb 21, 2025
BlackRock Institutional Trust Company, N.A.
58.22K
0.4%
--
--
Dec 31, 2024
Le (Goff Corinne)
53.00K
0.36%
--
--
Feb 21, 2025
The Vanguard Group, Inc.
48.81K
0.33%
--
--
Dec 31, 2024
Lindborg (Stacy R. Ph.D.)
28.06K
0.19%
+3.06K
+12.22%
Feb 21, 2025
Braun (Donald P)
25.60K
0.18%
--
--
Feb 21, 2025
XTX Markets LLC
21.41K
0.15%
+21.41K
--
Dec 31, 2024
Northern Trust Investments, Inc.
21.64K
0.15%
+18.40K
+567.70%
Dec 31, 2024
State Street Global Advisors (US)
21.30K
0.15%
--
--
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Date
Type
Ratio
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
